Akebia Therapeutics (AKBA) EBIAT (2016 - 2025)
Akebia Therapeutics (AKBA) has disclosed EBIAT for 9 consecutive years, with -$12.2 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 46.31% to -$12.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.3 million, a 92.3% increase, with the full-year FY2025 number at -$5.3 million, up 92.3% from a year prior.
- EBIAT was -$12.2 million for Q4 2025 at Akebia Therapeutics, down from $540000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $29.4 million in Q2 2022 to a low of -$83.0 million in Q2 2021.
- A 5-year average of -$25.1 million and a median of -$16.2 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: soared 135.46% in 2022, then tumbled 3814.01% in 2024.
- Akebia Therapeutics' EBIAT stood at -$69.9 million in 2021, then soared by 91.31% to -$6.1 million in 2022, then soared by 110.12% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then skyrocketed by 46.31% to -$12.2 million in 2025.
- Per Business Quant, the three most recent readings for AKBA's EBIAT are -$12.2 million (Q4 2025), $540000.0 (Q3 2025), and $247000.0 (Q2 2025).